MSB 3.19% 97.0¢ mesoblast limited

The macro environment is definitely not great for early stage...

  1. 13,916 Posts.
    lightbulb Created with Sketch. 124
    The macro environment is definitely not great for early stage biotechs stuck at preclinical or phase 1, which Mesoblast is not. They are very late stage so funding deals will be easier. Not a very long wait for new opportunistic partners.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.0¢
Change
0.030(3.19%)
Mkt cap ! $1.107B
Open High Low Value Volume
94.0¢ 98.0¢ 92.0¢ $3.342M 3.477M

Buyers (Bids)

No. Vol. Price($)
4 33313 97.0¢
 

Sellers (Offers)

Price($) Vol. No.
97.5¢ 73982 2
View Market Depth
Last trade - 16.10pm 03/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.